Covis, CDER Lay Out Arguments Ahead Of Makena’s Accelerated Approval Withdrawal Hearing

 
• By Sue Sutter

The company seeks to keep Makena on the market with a narrower indication while it conducts a new randomized, controlled trial in the US, but the FDA’s drugs center says keeping the drug on the market would render a new trial infeasible and do a disservice to women at risk for preterm birth.  

Narrow path
Covis' preferred path for Makena is to narrow the current indication while conducting a new randomized, controlled trial. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards